KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin (2018 - 2025)

Historic Gross Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 77.48%.

  • Castle Biosciences' Gross Margin fell 43300.0% to 77.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.94%, marking a year-over-year decrease of 19600.0%. This contributed to the annual value of 81.87% for FY2024, which is 23400.0% up from last year.
  • Castle Biosciences' Gross Margin amounted to 77.48% in Q3 2025, which was down 43300.0% from 79.55% recorded in Q2 2025.
  • Castle Biosciences' 5-year Gross Margin high stood at 86.73% for Q1 2021, and its period low was 75.17% during Q4 2022.
  • For the 5-year period, Castle Biosciences' Gross Margin averaged around 80.12%, with its median value being 80.96% (2024).
  • In the last 5 years, Castle Biosciences' Gross Margin crashed by -88600bps in 2022 and then soared by 60400bps in 2023.
  • Castle Biosciences' Gross Margin (Quarter) stood at 81.64% in 2021, then dropped by -8bps to 75.17% in 2022, then rose by 8bps to 81.21% in 2023, then increased by 0bps to 81.25% in 2024, then fell by -5bps to 77.48% in 2025.
  • Its last three reported values are 77.48% in Q3 2025, 79.55% for Q2 2025, and 81.38% during Q1 2025.